Melanoma Clinical Trial

YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey

Summary

To evaluate the effectiveness of the YERVOY® educational Risk Minimization (RM) tools in terms of awareness about these tools, their utilization, knowledge and comprehension of Immune Related Adverse Reaction (irAR)s, and appropriate behavior by Healthcare Professional (HCP)s and patients

View Full Description

Full Description

A total sample size of 160 to 200 HCPs and 160 to 200 patients

View Eligibility Criteria

Eligibility Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

HCP experienced in the treatment of patients with the research compound and patients that have received at least one dose

Study is for people with:

Melanoma

Estimated Enrollment:

158

Study ID:

NCT02224768

Recruitment Status:

Completed

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Bristol-Myers Squibb
Princeton New Jersey, 08540, United States
Local Institution
St. Ives Cambridgeshire, PE27 , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Estimated Enrollment:

158

Study ID:

NCT02224768

Recruitment Status:

Completed

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider